Literature DB >> 23559750

Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease.

Abdul Wadood1, Muhammad Riaz, Syed Babar Jamal, Masaud Shah, Muhammad Arif Lodhi.   

Abstract

NS3/4A protease is an important emerging target for the cure of hepatitis C. There are many inhibitors of HCV NS3/4A protease that are passing through the clinical improvement indicating momentous reduction in the viral infection rate of patients. In this study molecular docking via MOE-Dock program was used to evaluate binding interactions of ligands with HCV NS3/4A protease. The docking and experimental results were found in good correlation. The best conformations of ligands were analyzed for binding interactions with the residues of binding cavity of NS3/4A protease. The valuable binding interactions and docking scores were observed for compounds 01, 05, 06, 07, 08 and 09.

Entities:  

Keywords:  Binding interactions; HCV NS3/4A protease; Molecular Docking; inhibitors

Year:  2013        PMID: 23559750      PMCID: PMC3607190          DOI: 10.6026/97320630009309

Source DB:  PubMed          Journal:  Bioinformation        ISSN: 0973-2063


  21 in total

1.  A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.

Authors:  Nikolaus Schiering; Allan D'Arcy; Frederic Villard; Oliver Simic; Marion Kamke; Gaby Monnet; Ulrich Hassiepen; Dmitri I Svergun; Ruth Pulfer; Jörg Eder; Prakash Raman; Ursula Bodendorf
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Assessing the performance of OMEGA with respect to retrieving bioactive conformations.

Authors:  Jonas Boström; Jeremy R Greenwood; Johan Gottfries
Journal:  J Mol Graph Model       Date:  2003-03       Impact factor: 2.518

3.  Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target.

Authors:  Maxwell D Cummings; Jimmy Lindberg; Tse-I Lin; Herman de Kock; Oliver Lenz; Elisabet Lilja; Sara Felländer; Vera Baraznenok; Susanne Nyström; Magnus Nilsson; Lotta Vrang; Michael Edlund; Asa Rosenquist; Bertil Samuelsson; Pierre Raboisson; Kenneth Simmen
Journal:  Angew Chem Int Ed Engl       Date:  2010-02-22       Impact factor: 15.336

4.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.

Authors:  Keith P Romano; Akbar Ali; William E Royer; Celia A Schiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-17       Impact factor: 11.205

5.  Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.

Authors:  Nigel J Liverton; M Katharine Holloway; John A McCauley; Michael T Rudd; John W Butcher; Steven S Carroll; Jillian DiMuzio; Christine Fandozzi; Kevin F Gilbert; Shi-Shan Mao; Charles J McIntyre; Kevin T Nguyen; Joseph J Romano; Mark Stahlhut; Bang-Lin Wan; David B Olsen; Joseph P Vacca
Journal:  J Am Chem Soc       Date:  2008-03-14       Impact factor: 15.419

6.  Hepatitis C--pipeline update.

Authors:  Irena Melnikova
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

7.  Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.

Authors:  J L Kim; K A Morgenstern; C Lin; T Fox; M D Dwyer; J A Landro; S P Chambers; W Markland; C A Lepre; E T O'Malley; S L Harbeson; C M Rice; M A Murcko; P R Caron; J A Thomson
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

8.  Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation.

Authors:  R Bartenschlager; V Lohmann; T Wilkinson; J O Koch
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

9.  The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.

Authors:  R A Love; H E Parge; J A Wickersham; Z Hostomsky; N Habuka; E W Moomaw; T Adachi; Z Hostomska
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

Review 10.  A new standard of care for the treatment of chronic HCV infection.

Authors:  Wolf Peter Hofmann; Stefan Zeuzem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-05       Impact factor: 46.802

View more
  2 in total

1.  Cell Growth Stimulation, Cell Cycle Alternation, and Anti-Apoptosis Effects of Bovine Bone Collagen Hydrolysates Derived Peptides on MC3T3-E1 Cells Ex Vivo.

Authors:  Jianing Wang; Junli Liu; Yanchuan Guo
Journal:  Molecules       Date:  2020-05-14       Impact factor: 4.411

2.  In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.

Authors:  Abdul Wadood; Muhammad Riaz; Reaz Uddin; Zaheer Ul-Haq
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.